Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Clinical trial NCT06128551 · RECRUITING

Trial details

NCT number: NCT06128551
Sponsor: Revolution Medicines, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer (NSCLC)Colorectal Cancer Pancreatic Ductal Adenocarcinoma

Start date: 2023-11-14
Primary completion: 2028-12-01
Enrollment: 534

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.